Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | active not recruiting | Phase 3 | 898 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 24, 2026 | clinicaltrials |
| NCT05316324 | A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction | active not recruiting | Phase 3 | 353 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 |
| clinicaltrials |
| NCT07406542 | A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer | not yet recruiting | Phase 3 | 400 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07407517 | Adjuvant Intensification for LAR(POLARIS) | not yet recruiting | Phase 3 | 904 | Fudan UniversityOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT06135714 | Metastasis-directed Therapy for Oligometastases of Breast Cancer(OLIGAMI) | recruiting | Phase 3 | 340 | Tokyo Medical and Dental UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07385365 | A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer | not yet recruiting | Phase 3 | 3,142 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer(e3) | active not recruiting | Phase 3 | 1,939 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)(VIKTORIA-1) | active not recruiting | Phase 3 | 701 | Celcuity IncINDUSTRY | 23 | Feb 10, 2026 | clinicaltrials |
| NCT05909397 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer(VERITAC-3) | active not recruiting | Phase 3 | 59 | PfizerINDUSTRY | 10 | Feb 10, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT04639986 | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | active not recruiting | Phase 3 | 331 | Gilead SciencesINDUSTRY | 3 | Feb 9, 2026 | clinicaltrials |
| NCT07393321 | A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer | not yet recruiting | Phase 3 | 210 | Nanjing Chia-tai Tianqing PharmaceuticalINDUSTRY | 0 | Feb 6, 2026 | clinicaltrials |
| NCT02763566 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer(MONARCH plus) | active not recruiting | Phase 3 | 463 | Eli Lilly and CompanyINDUSTRY | 4 | Feb 5, 2026 | clinicaltrials |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer(MONARCH 3) | active not recruiting | Phase 3 | 493 | Eli Lilly and CompanyINDUSTRY | 22 | Feb 3, 2026 | clinicaltrials |
| NCT07382687 | Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype | not yet recruiting | Phase 3 | 248 | Fudan UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05439005 | Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.(OFOBA) | recruiting | Phase 3 | 158 | Institut CurieOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06704945 | No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy(Neo-NAUTILUS) | recruiting | Phase 3 | 464 | Seoul National University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07371910 | Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer | active not recruiting | Phase 3 | 200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07372144 | Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment(IARA) | not yet recruiting | Phase 3 | 227 | D'Or Institute for Research and EducationOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07024173 | A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | recruiting | Phase 3 | 240 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07366840 | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure(BRIGHT) | not yet recruiting | Phase 2 / Phase 3 | 268 | Fudan UniversityOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07362914 | Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions(CHORD) | recruiting | Phase 3 | 182 | Fudan UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06519370 | FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | active not recruiting | Phase 3 | 350 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06830889 | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy | recruiting | Phase 3 | 1,450 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05909332 | Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | recruiting | Phase 3 | 764 | Fudan UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06957886 | A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer | recruiting | Phase 3 | 566 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07019363 | CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) | recruiting | Phase 3 | 1,903 | Fudan UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07350928 | Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status | recruiting | Phase 3 | 394 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05169567 | Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer(postMONARCH) | active not recruiting | Phase 3 | 368 | Eli Lilly and CompanyINDUSTRY | 17 | Jan 16, 2026 | clinicaltrials |
| NCT05860465 | Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 2 / Phase 3 | 254 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04320979 | Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients | active not recruiting | Phase 3 | 2,400 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04290793 | Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | active not recruiting | Phase 2 / Phase 3 | 113 | Hebei Medical University Fourth HospitalOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02051218 | Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks | active not recruiting | Phase 3 | 1,380 | Swiss Cancer InstituteOTHER | 3 | Dec 30, 2025 | clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT07294534 | A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer | not yet recruiting | Phase 2 / Phase 3 | 817 | Shanghai Henlius BiotechINDUSTRY | 0 | Dec 19, 2025 | clinicaltrials |
| NCT04722978 | Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 228 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07088263 | Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer | recruiting | Phase 3 | 192 | Sun Yat-sen UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07269691 | RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer | not yet recruiting | Phase 3 | 194 | Pengfei QiuOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06787118 | Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer(PANDORA) | not yet recruiting | Phase 3 | 130 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06781996 | A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer(HOPE) | recruiting | Phase 3 | 180 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT04193059 | Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer(PANSY) | active not recruiting | Phase 3 | 1,560 | Fudan UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04514419 | Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | active not recruiting | Phase 3 | 408 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04565054 | Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC(ADAPTlate) | active not recruiting | Phase 3 | 1,260 | Women's Cancer Study Group GmbHOTHER | 3 | Nov 19, 2025 | clinicaltrials |
| NCT06144164 | A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer | recruiting | Phase 3 | 285 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT02107703 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer(MONARCH 2) | active not recruiting | Phase 3 | 669 | Eli Lilly and CompanyINDUSTRY | 20 | Oct 21, 2025 | clinicaltrials |
| NCT03529110 | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] | active not recruiting | Phase 3 | 524 | Daiichi SankyoINDUSTRY | 15 | Oct 21, 2025 | clinicaltrials |
| NCT06265428 | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | active not recruiting | Phase 3 | 228 | DualityBio Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2026source: clinicaltrials